Perspective Therapeutics Inc (CATX) Stock Price, Quote & News

Company Profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a b...

Industry: Medical Devices

Sector: Healthcare

Phone: 206 676 0900

Website: www.perspectivetherapeutics.com

Address:

2401 Elliott Avenue, Suite 320, Seattle, United States

RadioIsotope25 Sep. 12 at 6:22 AM

Radiopharma hot Lilly partners with Aktis, deepening radiopharma investment | BioPharma Dive $CATX $RADX https://www.biopharmadive.com/news/aktis-eli-lilly-radiopharmaceuticals-cancer-deal/716700/

1 · Reply

Jcljack26 Sep. 11 at 8:04 PM

$CATX Once $LNTH is done with their dumping, we can start to move back up.

1 · Reply

RadioIsotope25 Sep. 11 at 7:27 PM

$CATX Complete Reversal

1 · Reply

David_M_ Sep. 11 at 6:53 PM

$CATX Added.

0 · Reply

Y007 Sep. 11 at 3:10 PM

$CATX standard accumulation shakeout before major catalyst … whales are not able to BUY millions of shares on open market because it would cause price to spike they purposely do this to accumulate shares… If anything lantheus loving this as an insider that’s looking to do the buyout they get nice discount on the company the lower the price they might even be behind it lol If you calculate cash + buildings = $2.84 is breakeven meaning the actual science is trading at a negative value right now MAJOR DISCOUNT

1 · Reply

CM62 Sep. 11 at 2:42 PM

$CATX Why is the SP down again?

1 · Reply

rughead64 Sep. 11 at 2:26 PM

$CATX 500k traded. Someone dumping

0 · Reply

RadioIsotope25 Sep. 11 at 2:09 PM

Short squeeze p&l scenario if we see 45% Orr then 50% Orr in Nov on 30,000 shares long $CATX

0 · Reply

RadioIsotope25 Sep. 11 at 1:39 PM

$CATX Why present bad data twice at major conferences. 50% Orr coming I knew it

0 · Reply

RadioIsotope25 Sep. 11 at 1:36 PM

$CATX This could cause shorts to die on the vine

0 · Reply

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

2026-08-18T20:35:10.000Z - 26 days ago

BMO Capital starts Perspective at Outperform, cites pipeline opportunities

2026-08-18T20:25:30.000Z - 26 days ago

Perspective Therapeutics initiated with an Outperform at BMO Capital

2026-08-16T13:45:47.000Z - 4 weeks ago

Perspective Therapeutics price target lowered to $5 from $6 at BofA

2026-08-11T11:01:16.000Z - 4 weeks ago

Perspective Therapeutics price target lowered to $14 from $16 at Piper Sandler

Aug 10, 2026, 4:00 PM EDT - 4 weeks ago

Perspective Therapeutics Earnings release: Q2 2026

Aug 10, 2026, 4:00 PM EDT - 4 weeks ago

Perspective Therapeutics Quarterly report: Q2 2026

Jul 31, 2026, 6:30 AM EDT - 6 weeks ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

2026-07-28T10:47:15.000Z - 6 weeks ago

Perspective Therapeutics: EC grants OMP designation to (212Pb)VMT-alpha-NET

Jul 28, 2026, 6:30 AM EDT - 6 weeks ago

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

Jul 17, 2026, 12:22 PM EDT - 1 month ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

2026-07-10T17:55:37.000Z - 2 months ago

Perspective Therapeutics management to meet virtually with BTIG

Jul 8, 2026, 6:30 AM EDT - 2 months ago

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.

2026-06-26T19:25:28.000Z - 2 months ago

Perspective Therapeutics management to meet virtually with BTIG

2026-06-03T11:10:47.000Z - 3 months ago

Perspective announces first patient dosed with (212Pb)VMT-alpha-NET

Jun 3, 2026, 6:30 AM EDT - 3 months ago

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

May 21, 2026, 5:51 PM EDT - 3 months ago

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

May 19, 2026, 2:05 PM EDT - 3 months ago

Perspective Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-18T10:35:48.000Z - 3 months ago

Perspective Therapeutics doses first patients in two Phase 1/2a studies

May 18, 2026, 6:30 AM EDT - 3 months ago

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

May 13, 2026, 5:20 PM EDT - 4 months ago

Perspective Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T16:04:03.000Z - 4 months ago

Perspective Therapeutics price target lowered to $6 from $7 at BofA

2026-05-11T23:16:42.000Z - 4 months ago

Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)

May 11, 2026, 4:07 PM EDT - 4 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

May 11, 2026, 4:00 PM EDT - 4 months ago

Perspective Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 4 months ago

Perspective Therapeutics Quarterly report: Q1 2026

Apr 24, 2026, 6:30 AM EDT - 4 months ago

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

2026-04-20T10:10:51.000Z - 4 months ago

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

Apr 20, 2026, 6:00 AM EDT - 4 months ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Perspective Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Perspective Therapeutics Proxy statement: Proxy filing

Apr 2, 2026, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences

2026-03-23T10:10:08.000Z - 5 months ago

Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright

2026-03-19T12:28:39.000Z - 5 months ago

Perspective Therapeutics price target raised to $8 from $7 at UBS

2026-03-18T12:51:16.000Z - 5 months ago

Perspective Therapeutics price target raised to $13 from $11 at B. Riley

2026-03-18T12:07:41.000Z - 5 months ago

Perspective Therapeutics price target raised to $8 from $7 at UBS

Mar 17, 2026, 4:45 PM EDT - 6 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Mar 16, 2026, 4:07 PM EDT - 6 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Mar 16, 2026, 4:00 PM EDT - 6 months ago

Perspective Therapeutics Annual report: Q4 2025

Mar 16, 2026, 4:00 PM EDT - 6 months ago

Perspective Therapeutics Earnings release: Q4 2025

2026-02-19T10:15:14.000Z - 6 months ago

Perspective Therapeutics initiated with an Overweight at Piper Sandler

Feb 17, 2026, 7:00 AM EST - 6 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Feb 2, 2026, 8:35 AM EST - 7 months ago

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Jan 14, 2026, 5:15 PM EST - 8 months ago

Perspective Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 7:00 AM EST - 8 months ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Dec 18, 2025, 7:00 AM EST - 8 months ago

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 1:00 PM EST - 9 months ago

Perspective Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 7:00 AM EST - 9 months ago

Perspective Therapeutics to Participate in Upcoming December Conferences

Nov 10, 2025, 4:05 PM EST - 10 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Nov 10, 2025, 4:00 PM EST - 10 months ago

Perspective Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 10 months ago

Perspective Therapeutics Earnings release: Q3 2025

Oct 31, 2025, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Participate in Upcoming November Conferences

Oct 24, 2025, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 20, 2025, 8:30 AM EDT - 10 months ago

Perspective Therapeutics Transcript: Study Update

Oct 20, 2025, 8:30 AM EDT - 10 months ago

Perspective Therapeutics Press release: Study Update

Oct 20, 2025, 8:30 AM EDT - 10 months ago

Perspective Therapeutics Slides: Study Update

Oct 20, 2025, 4:00 AM EDT - 10 months ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Sep 3, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Aug 26, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 13, 2025, 9:30 AM EDT - 1 year ago

Perspective Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 9:30 AM EDT - 1 year ago

Perspective Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 6:45 AM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Jul 24, 2025, 12:45 PM EDT - 1 year ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 15, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jun 21, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

May 30, 2025, 5:21 PM EDT - 1 year ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 12, 2025, 4:36 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 12, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Earnings release: Q1 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Apr 23, 2025, 12:25 PM EDT - 1 year ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 26, 2025, 4:10 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 26, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Annual report: Q4 2024

Mar 26, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Earnings release: Q4 2024

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 11, 2025, 3:30 PM EDT - 1 year ago

Perspective Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 3, 2025, 11:10 AM EST - 1 year ago

Perspective Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 21, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 12, 2025, 2:00 PM EST - 1 year ago

Perspective Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 5, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Transcript: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Press release: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Slides: Status Update

Jan 24, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 15, 2025, 6:45 PM EST - 1 year ago

Perspective Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Dec 5, 2024, 10:50 AM EST - 1 year ago

Perspective Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 10:00 AM EST - 1 year ago

Perspective Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 18, 2024, 9:10 AM EST - 1 year ago

Perspective Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 13, 2024, 5:45 PM EST - 1 year ago

Perspective Therapeutics Transcript: UBS Global Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Nov 12, 2024, 4:00 PM EST - 1 year ago

Perspective Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Perspective Therapeutics Earnings release: Q3 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

RadioIsotope25 Sep. 12 at 6:22 AM

Radiopharma hot Lilly partners with Aktis, deepening radiopharma investment | BioPharma Dive $CATX $RADX https://www.biopharmadive.com/news/aktis-eli-lilly-radiopharmaceuticals-cancer-deal/716700/

1 · Reply

Jcljack26 Sep. 11 at 8:04 PM

$CATX Once $LNTH is done with their dumping, we can start to move back up.

1 · Reply

RadioIsotope25 Sep. 11 at 7:27 PM

$CATX Complete Reversal

1 · Reply

David_M_ Sep. 11 at 6:53 PM

$CATX Added.

0 · Reply

Y007 Sep. 11 at 3:10 PM

1 · Reply

CM62 Sep. 11 at 2:42 PM

$CATX Why is the SP down again?

1 · Reply

rughead64 Sep. 11 at 2:26 PM

$CATX 500k traded. Someone dumping

0 · Reply

RadioIsotope25 Sep. 11 at 2:09 PM

Short squeeze p&l scenario if we see 45% Orr then 50% Orr in Nov on 30,000 shares long $CATX

0 · Reply

RadioIsotope25 Sep. 11 at 1:39 PM

$CATX Why present bad data twice at major conferences. 50% Orr coming I knew it

0 · Reply

RadioIsotope25 Sep. 11 at 1:36 PM

$CATX This could cause shorts to die on the vine

0 · Reply

RadioIsotope25 Sep. 11 at 1:27 PM

This is good news for $CATX It creates a second major VMT-α-NET catalyst shortly after ESMO: October 19: ESMO abstract October 23–27: ESMO presentation November 4: details/abstract for the EORTC-NCI-AACR presentation November 18–20: presentation of updated VMT-α-NET data

0 · Reply

Y007 Sep. 11 at 1:18 PM

$CATX $12 PT

1 · Reply

RadioIsotope25 Sep. 11 at 1:00 PM

$CATX : CATX evidently believes the evolving data are strong enough for another competitive scientific presentation. Shorts can’t simply wait for ESMO and assume the catalyst is finished; another dataset follows within weeks. If ESMO shows approximately 40%–45% ORR with clean kidney safety, the November update offers a chance for responses to deepen or additional patients to convert. It also gives CATX another opportunity to support the Phase 3 dose and registration plan. It doesn’t guarantee the November data are better, and acceptance itself isn’t proof of positive results. But this is unquestionably incrementally bullish and reduces the “nothing after ESMO” concern. It makes holding a large short through October and November considerably riskier.

1 · Reply

josephfuller Sep. 11 at 12:07 PM

$CATX Or Lantheus Is Pissed We Won’t Sell To Them. ?. Do We Still Owe Them First Dibs On VMT-A-Net If They Are Bailing. ?.

1 · Reply

josephfuller Sep. 11 at 12:02 PM

$CATX Closing In On Under $300 Million Dollar Market Cap. And Short’s Not Moving 🤣😂🤣 That’s Crazy 🤷‍♂️🤷‍♂️.

0 · Reply

josephfuller Sep. 11 at 11:59 AM

$CATX We Know We Are “SAFEST”. We Brag Of That And Have Proven That. BUT OUR ORR MUST Not Be Impressive Enough 🤷‍♂️☹️. 🤷‍♂️

0 · Reply

josephfuller Sep. 11 at 11:56 AM

$CATX News Must Not Be Shattering That’s Coming 🤷‍♂️ ☹️. I Can’t Explain This.

1 · Reply

JDinvestments Sep. 11 at 11:55 AM

$CATX on watch for STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂

0 · Reply

Xanderzzzzzzz Sep. 11 at 10:49 AM

$CATX

0 · Reply

rughead64 Sep. 11 at 10:33 AM

$CATX news

1 · Reply

focafoca99 Sep. 11 at 10:27 AM

$CATX announced its VMT-α-NET data were accepted for poster presentation at the 38th EORTC-NCI-AACR Symposium in November.

1 · Reply

rughead64 Sep. 11 at 9:53 AM

$CATX short interest 23.35 million. 2nd highest all time. Seems like they are in no hurry to cover

1 · Reply

Market Cap	320.77M
Revenue (ttm)	880,000.00
Net Income (ttm)	-103.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11,718.18%
Debt to Equity Ratio	0.00

Volume	2,024,700
Avg Vol	1,311,028
Day's Range	N/A - N/A
Shares Out	114.15M
Stochastic %K	25%
Beta	1.80
Analysts	Strong Sell
Price Target	$12.47